Alnylam pharmaceuticals, inc. (ALNY)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08
Revenues:
Total revenues

219,750

74,908

89,912

47,159

41,097

50,561

47,167

66,725

82,757

100,041

100,533

96,163

Operating costs and expenses:
Cost of goods sold

25,062

1,802

0

-

-

-

-

-

-

-

-

-

Research and development

655,114

505,420

390,635

382,392

276,495

190,249

112,957

86,569

99,295

106,384

108,730

96,883

Selling, general and administrative

479,005

382,359

199,365

89,354

60,610

44,526

27,152

44,612

38,280

37,727

39,914

27,115

Total operating costs and expenses

1,159,181

889,581

590,000

471,746

337,105

455,541

140,109

196,181

137,575

144,111

148,644

123,998

In-process research and development

-

-

-

-

-

220,766

-

-

-

-

-

-

Restructuring of Tekmira license agreement

-

-

-

-

-

-

-

65,000

-

-

-

-

Loss from operations

-939,431

-814,673

-500,088

-424,587

-296,008

-404,980

-92,942

-129,456

-54,818

-44,070

-48,111

-27,835

Other income:
Equity in loss of joint venture (Regulus Therapeutics Inc.)

-

-

-

-

-

-

-

-4,522

-3,505

-7,639

-4,910

-9,290

Gain on issuance of stock by Regulus Therapeutics Inc.

-

-

-

-

-

-

-

16,084

-

4,421

-

-

Interest income

33,448

29,262

12,236

8,308

5,859

2,559

1,069

977

1,205

2,305

5,385

14,414

Interest expense

-

-

-

-

-

-

-

-

-

-

-

872

Other income

11,308

4,173

-3,022

6,171

76

1,817

-47

331

-531

1,982

628

-1,947

Change in fair value of liability obligation

9,422

0

0

-

-

-

-

-

-

-

-

-

Gain on litigation settlement

0

20,564

0

-

-

-

-

-

-

-

-

-

Total other income

54,178

53,999

9,214

14,479

5,935

4,376

1,022

12,870

-2,831

1,069

1,103

2,305

Loss before income taxes

-885,253

-760,674

-490,874

-410,108

-

-400,604

-91,920

-116,586

-57,649

-43,001

-47,008

-25,530

Provision for income taxes

900

823

0

0

-

-40,209

-2,695

-10,572

0

514

582

719

Net loss

-886,116

-761,497

-490,874

-410,108

-290,073

-360,395

-89,225

-106,014

-57,649

-43,515

-47,590

-26,249

Net loss per common share - basic and diluted (in dollars per share)

-8.11

-7.57

-5.42

-4.79

-3.45

-4.85

-1.45

-2.11

-1.36

-1.04

-1.14

-0.64

Weighted-average common shares used to compute basic and diluted net loss per common share (in shares)

109,264

100,590

90,554

85,596

83,992

74,278

61,551

50,286

42,410

42,040

41,633

41,077

Statements of Comprehensive Loss
Net loss

-886,116

-761,497

-490,874

-410,108

-290,073

-360,395

-89,225

-106,014

-57,649

-43,515

-47,590

-26,249

Unrealized gain on marketable debt securities

558

1,220

-2,886

-30,833

-44,394

31,127

4,055

15,827

-879

27

-349

833

Foreign currency translation

-343

0

0

-

-

-

-

-

-

-29

-121

53

Defined benefit pension plans, net of tax

3,520

0

0

-

-

-

-

-

-

-

-

-

Reclassification adjustment for realized loss on marketable securities included in net loss

0

0

-1,894

6,977

-

2,081

-

-

-

-

-

-

Comprehensive loss

-889,421

-760,277

-491,866

-447,918

-334,467

-331,349

-85,170

-90,187

-58,528

-43,517

-48,060

-25,363

Research and development

-

-

-

-

-

-

-

-

-

-

11,415

9,575

General and administrative

-

-

-

-

-

-

-

-

-

-

8,312

6,807

Net product revenues
Total revenues

166,537

12,535

0

-

-

-

-

-

-

-

-

-

Net revenues from collaborations
Total revenues

53,213

62,373

89,912

47,159

-

-

-

-

-

-

-

-